Clinical trials: Depressive Episode
Major Depressive Episode Associated With Bipolar II Disorder
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder.
- Trial name
- NCT06429722
- Testing
- NMRA-335140 80 mg
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neumora Therapeutics, Inc.
Depressive Episode, Depression
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the…
- Conditions
- Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- SAMDE (NCT05708222)
- Testing
- MEB-001
- Where
- 13 sites in United States
- Volunteers
- 715 people
- Sponsor
- Medibio Limited
Bipolar Disorder
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
To evaluate the efficacy of ramelteon for treatment of acute depressive episodes associated with Bipolar 1 Disorder.
- Trial name
- NCT01677182
- Testing
- Ramelteon
- Where
- 104 sites in United States, Bulgaria and 8 more
- Volunteers
- 535 people
- Sponsor
- Takeda
Depression, Depressive Disorders
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517.
- Conditions
- Depression, Depressive Disorders, Psychotic Disorders
- Trial name
- Hermes (NCT00212797)
- Testing
- Org 34517
- Volunteers
- 273 people
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar I or II Disorder
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with…
- Trial name
- NCT07220460
- Testing
- ABBV-932
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 84 people
- Sponsor
- AbbVie
Bipolar Depression
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar…
- Trial name
- NCT02362412
- Testing
- FK949E
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Astellas Pharma Inc
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Major Depressive Disorder (MDD)
Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode
The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from…
- Trial name
- EMC1 (NCT06601140)
- Testing
- EMOCARE software
- Where
- 11 sites in France
- Volunteers
- 104 people
- Sponsor
- Emobot
Major Depressive Disorder
An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
The primary objective of this study is to evaluate the efficacy of 3 fixed doses of SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major Depressive Disorder (MDD), based on the 17-item Hamilton…
- Trial name
- FIDELIO (NCT00822744)
- Testing
- SSR411298, Escitalopram
- Where
- 7 sites in Chile, Mexico and 5 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Bipolar Disorder, Major Depressive Disorder
Evaluation of the Impact of the EDIT-B® Blood Test on the Health Status of Patients Presenting a Major Depressive Episode. Clinical Utility and Medico-Economic Aspects
Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior.
- Trial name
- SEM EDIT-B (NCT06507787)
- Testing
- EDIT-B test, EDIT-B test (without giving result)
- Where
- 7 sites in France
- Volunteers
- 450 people
- Sponsor
- Alcediag
Major Depressive Disorder
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT06419608
- Testing
- BHV-7000
- Where
- 62 sites in United States
- Volunteers
- 336 people
- Sponsor
- Biohaven Therapeutics Ltd.
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorders
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Primary objective : To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
- Trial name
- NCT00825058
- Testing
- amibegron (SR58611A), paroxetine
- Where
- 8 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Depressive Disorder, Major Depressive Disorder
Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder
This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks.
- Conditions
- Depressive Disorder, Major Depressive Disorder, Depressive Episode
- Trial name
- NCT05701345
- Testing
- OMNIFIT DTx-MDD, standard treatment
- Where
- 5 sites in South Korea
- Volunteers
- 162 people
- Sponsor
- Omni C&S
Bipolar Disorder, New Occurred Episode
Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR
The primary purpose of the study is to explore management of symptomatology in patients with bipolar disorder that experience a new manic,depressive or mixed episode and are treated with Seroquel XR monotherapy/adjuctive, in…
- Trial name
- NCT01029145
- Where
- 30 sites in Romania
- Volunteers
- 537 people
- Sponsor
- AstraZeneca
Bipolar I Disorder
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo).
- Trial name
- Illuminate1 (NCT07494305)
- Testing
- LB-102
- Where
- 26 sites in United States
- Volunteers
- 320 people
- Sponsor
- LB Pharmaceuticals Inc.
Depressive Episode, Bipolar 1 Depression
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
A clinical study to test the effectiveness of an investigational drug to treat people that have major depressive episodes when they have Bipolar 1 Depression
- Trial name
- NCT03543410
- Testing
- SEP-4199 200 mg, SEP-4199 400 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 344 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Major Depressive Disorder
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis
This is a retrospective chart review study to determine if Deplin® 7.5mg-15mg combined with an antidepressant is better than an antidepressant alone in adults with major depression.
- Trial name
- NCT01001559
- Testing
- L-methylfolate, Selective serotonin reuptake inhibitor (SSRI), Serotonin and norepinephrine reuptake inhibitor (SNRI)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Pamlab, Inc.
Major Depressive Disorder
Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of three fixed dosages of Lu AA34893 compared to placebo in the treatment of patients with Major Depressive Disorder.
- Trial name
- NCT00766870
- Testing
- Lu AA34893, Venlafaxine extended release
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S